Clinical Trial Update: Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating quetiapine fumarate extended-release as monotherapy for bipolar depression has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Depression

Drugs mentioned

• SEROQUEL XR (Quetiapine)

Snippet

Sponsor: AstraZeneca | Conditions: Bipolar Depression | Phase 3 | Status: COMPLETED | Results posted: 2016-02-03